Oculis plans to list on Nasdaq

Oculis and European Biotech Acquisition Corp, a special purpose acquisition company (SPAC), have announced that they have entered into a definitive agreement to combine their businesses. Following this transaction, the company will be renamed "Oculis Holding SA" and will work to accelerate the development of Oculis' specialty ophthalmology pipeline. The combined company will be listed on Nasdaq, the US stock exchange, with an estimated enterprise value of around $220 million. Along with the Nasdaq listing, Oculis has secured the commitment of multiple investors for an expanded PIPE and a private equity investment of nearly $80 million.

Northstack, a news web about Icelandic tech, start-ups and venture, first published news about the merger and the stock exchange listing.

Oculis, headquartered in Lausanne, Switzerland and with operations in Europe and the United States, is a biopharmaceutical company focused on developing innovative eye treatments to improve vision and the lives of patients. The company was founded in 2003 by dr. Einar Stefánsson, professor of ophthalmology, and dr. Þorsteinn Loftsson, professor of pharmacology, who still lead research and development within the company.

Oculis is among the Iceland Health Tech Cluster's founding members.